


BEST AVAILABLE COPY

GNE.3030R1C6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Goddard et al. (as amended)
Appl. No. : 10/036,063
Filed : December 26, 2001
For : ANTIBODIES TO POLYPEPTIDES
THAT INDUCE CELL
PROLIFERATION (as amended)
Examiner : Kolker, Daniel E.
Group Art Unit : 1646



DECLARATION UNDER 37 CFR §1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We declare and state as follows:

1. We are the inventors of the invention claimed in the above-captioned patent application.
2. During the time period in which we participated in the events and activities described herein, we were employed by Genentech, Inc., the assignee of the above-captioned application.
3. All of the events and activities described herein were performed by us personally, or by others at our direction as part of our duties as employees of Genentech, Inc.
4. The invention claimed in the above-captioned patent application was conceived and reduced to practice in the United States prior to November 18, 1999 as described below.
5. Prior to November 18, 1999, we conceived of the invention claimed in the above-captioned patent application. This is demonstrated by the attached sequence printout (Exhibit A), which was generated prior to November 18, 1999, and which shows the complete sequence of the nucleic acid having the sequence of SEQ ID NO: 56. The attached printout also shows the complete sequence of the polypeptide which has the sequence of SEQ ID NO: 57. As evidenced by the sequence printout, we were in possession of the complete nucleic acid and amino acid sequences prior to November 18, 1999.
6. The date deleted from Exhibit A is prior to November 18, 1999. This date was redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.
7. After these initial experiments, we diligently reduced the claimed subject matter to practice by working to express and purify the encoded polypeptide and to run it systematically through many assays. The cDNA was deposited with the American Type Culture Collection (ATCC) on April 20, 1999 and assigned ATCC no. 203948. The protein of interest was assigned a "protein inventory

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: 
Audrey Goddard

Date: June 7/05

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____

Andrey Goddard

By: _____

Paul J. Godowski

By: _____

Austin L. Gurney

By: _____

James Pan

By: _____

Colin K. Watanabe

By: _____

William I. Wood

Date: _____

Date: 5/31/05

Date: _____

Date: _____

Date: _____

Date: _____

1723199
052005

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: 6/8/05

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan 

Date: June 9/05

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: Colin K. Watanabe
Colin K. Watanabe

Date: 6/8/2005

By: _____
William I. Wood

Date: _____

1723199
052005

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____ 5/27/05

1723199
052005

EXHIBIT A

EXHIBIT B

>Thursday, April 28, 2005
>DNA92234 [Full]
>887 Sites [All Sites]
> [DNA92234], sheldens
> Lib309

>Sequence confirmed by phredphrap

thAI
nlaIII snaBI
sphI fnuDII/mvnI mnII
nspHI bstUI tail taqI
tail nsPI bsh1236I xbaI
maeII/hpyCH4IV bsiWI/spI tsp509I[M.ecori-]
aluI hinII/acyI cac8I bsaAI ecoRI tliI
tsp45I ahaII/bsaHI mluI rsAI hpy188I smII
maeIII mboII aatII cac8I afI III maeII/hpyCH4IV paeR7I hpy188I acII
hphI sfcI earI/ksp632I hpy99I hpyCH4V csp6I aluI apoI avai[M.taqI-] mnII fnu4HI/bsoFI hpy18
1 TAGGTGACAC TATAGAAGAG CTATGACCGT GCATGGCACGC GTACGTAAGC TGGAATTTCG GCTCGAGGAA TGATAACCTC CGAAGCCGCT TTGTTCTCCA
ATCCACTGTG ATATCTCTC GATACTGCAG CGTACGTGCG CATGCATTAGC AGCCCTTAAGC CGAGCTCCCT ACTTATGGAG GCTTCGGCGA AACAAAGGTT

^insert starts here

scrFI [dcm-]	mnlI
bspGI	bpmI / gsuI [dcm-]
mvaI	sau3AI
ecoRII [dcm-]	scrFI [dcm-]
dsAV [dcm-]	pspGI
mboI / ndeII [dam-]	mvaI
bstNI	ecoRII [dcm-]
dpmII [dam-]	dsAV [dcm-]
bsp1286	bstXI / xbaII
bmyI	bssKI [dcm-]
bssKI [dcm-]	bstNI
bpy188I	fokI
apyI [dcm+] dpnI [dam+]	ribolI cac8I
eco57I	tsp509I
bsaII	bstF5I
bgI	mnlI
banII	apoI
bpmI / gsuI [dcm-]	earI / ksp632I
mwoI	bsaII
CGCCCTCAGA	TTGAGGGAT
GCCCTGGAGC	GGAAAGGGCT
AAGATCTTCC	GGCTCTGTG
TGTGAATAATC	CCCTGGAGGA
AAATTCAATCA	ACTTGAGAA
TTGAGGGAT	ACTTGAGAA
AACTCCCTA	GGGACCTCC
CCTTCTCCGA	TGAACACCT
TTAACTAGTAGT	TGAACACCT
801 GCGGAAGTCTGGGACCTCTCG	TTAACTAGTAGT
TTAACTAGTAGT	AACTCCCTA
TTAACTAGTAGT	CCTTCTCCGA
TTAACTAGTAGT	CCGAGACAAAC
TTAACTAGTAGT	TGAACACCT
179 A F R A L E Q D L P V N I K F I I E G M E E G S V A L E E L V E	

scrFI [
ncII
mspI
hpAI
dsAV
bsSKI
bsaJI
xmaI/ps
smaI
scrFI [M
ncII
dsAV
sau3AI
mboI/ndeII [dam-]
bsSKI
bsaJI
avaII [M.
tflI
mboII
sau96I
hinfI
avaII
hinfI
tsp509I
hpy188I
dpnII [dam-]
dpnI [dam+]
alwI [dam-]
alwI [dam+]
cac8I
nlaIV
901 AAAGAAAAAGG ACCGATTCTT CTCCTGGTGTG GACTACATTG TAATTTCAGA TAAACCTGTGG ATCAGCCAAA GGAAGGCCAGC AATCACTTAT GGAAACCCGGG
TTTCTTTTCC TGCGCTAAGAA GAGACCAAC CTGATGTAAC ATAAAGTCT ATTGGACACC TAGTCGGTT CCTTCGGTGC TTAGTGAATA CCTTGGCCC
212 K E R F F S G V D Y I V I S D N L W I S Q R K P A I T Y G T R G

scrFI [dcm-]				
pspGI				
mvaI				
ecorII [dcm-]				
dsaV [dcm-]				
bstNI				
	bssKI [dcm-]			
	bsmAI	hpy188III		
	bsAI	ddeI nlaIV	fokI	rcaI
	hphI	hpyCH4V apyI [dcm+]	bstF5I	hpy188III
	mlnII	hpyCH4V apyI [dcm+]	sfaNI	bsPHI
aluI	nlaIII	hpyCH4V apyI [dcm+]	bsPCNI	dpnI [dam+] ea
1001	GGAACAGCTA	CITCATGGTG	TCAGGAAACCT	TGGTGGCAT CCAATGGCTG ATCTGGTTGC
	GAGGTGAAAT	GGATTTCAC	CGTCTCTGGT	CCTTGTCGAT GAAGTACCACTTA CGTCTCTGGT CCTAAAAGTG AGTCCTTGGA AACCAACCGTA GGAAGTACTT GGTTACCGAC TAGACCAACG
246	N S Y F M V E V K C R D Q	D F H S G T F G G I L H E P M A D L V A		

scrFI [dcm-]						
pspGI						
mvaI						
ecoRII [dcm-]						
dsaV [dcm-]						
bstNI						
bssKI [dcm-]						
sau96I [dcm-]						
nlaIV						
accI	avalII [dcm-]					
scrFI [dcm-]	scrFI [dcm-]					
pspGI p1eI	apyI [dcm+]					
mvaI mlyI	mvaI bsmFI					
ecoRII [dcm-]	ecoRII [dcm-]					
dsaV [dcm-]	dsaV [dcm-]					
bstNI hinfI	bstNI bsAI					
bssKI [dcm-]	bssKI [dcm-] tfI	xmnI	nlaIV			
apyI [dcm+]	apyI [dcm+]	hinfI				
mboII		asp700				
1101 TCTTCTCGGT AGCCTGGTAG ACTCGTCTGG TCATATCCCTG GTCCCTGGAA TCTATGATGA AGTGGTTCCCT CTTACAGAAG AGGAAATAAA TACATACAAA AGAAGAGCCA TCGGACCATC TGAGCAGACC AGTATAGGC CAGGGACCT AGATACTACT TCACCAAGGA GAATGTCCTC TCCTTTATT ATGTAIGTTT						
279 L L G S L V D S S G H I L V P G I Y D E V V P L T E E I N T Y K						

			P1
mlaIII	tsp45I		ml
msII	maeIII	mbII	hi
mlII msII	acII	hpy188III	nlalII
1401 CCCTCACATG AATGTGTCTG CGAGGTGACA CGACATCTG AAGATGTGTT CTCCAAAAAGA AATAGTCCA ACAAGATGGT TGTTCCATG GGGAGTGTAC TTACACAGAC GCCACCTTT TGTCCACTGT GCTGTAGAAC TTCTACACAA GAGGTTTCT TTATCAAGGT TGTTCTACCA ACAAAGGTAC			
379 P H M N V S A V E K Q V T R H L E D V F S K R N S S N K M V V S M			
			sau
			sau3AI bst4CI/hpYCH4III
			mboI
			dpn
			alw
			hpy188I
rmaI	dsaI		
maeI	btgI/bstDSI sspI		
bfaI	bsaJI hpyCH4V	bsrI	
1501 ACTCTAGGAC TACACCCGTG GATTGCCAAT ATTGATGACA CCCAGTATCT CGCAGCAAA AGAGGGATCA GAACAGTGTGTT TGGAACAGAA CCAGGATATGA TGAGATCCCTG ATGTGGGCAC CTAACGTTA TAACTACTGT GGTCATAGA GGGTCATAGA GCGTCGTTT TCTCGCTAGT CTTGTCACAA ACCTTGTCTT GGTCTATACT			
412 T L G L H P W I A N I D D T Q Y L A A K R A I R T V F G T E P D M I			

	scrFI [dcm-]
	pspGI
	mvaI
	ecoRII [dcm-]
	dsaV [dcm-]
	bstNI
tseI	
cac8I	fnu4HI/bsoFI
	fnu4HI/bsoFI
	bbvI
sm1I	aluI
mn1I	hpyCH4V
2001	CCTTCCTCAA GTCATAGCTG CTGGAGCAA CTGTGATTTC CCAAGTCCTG TGCAATAGCC CCAGGATTGG ATTCCCTCCA ACCCTTTAGC ATATCTCAA
	GGAAGGAGTT CAGTATCGAC GAACGTCGTT GAACTAAAGG GGTCAAGAC ACGTTATCGG GGTCAGGAC AGCTTAACC TAAGGAAGGT TGGAAAATCG TATAAGGTT
	sau96I
	avall
	bssSI
	ppuMI
	hgIAI/asPHI
	ecoO109I/draII hpy188III
	sau3AI
	mboI/ndeII [dam-]
	rmaI
	hpaII
	bsaWI
	mspI
	tsp509I
	hpyCH4V
2101	CCTTGCAATT TGATTTGGCAT AATCACTCCG GTTGTGCTTC TAGGTCTCTCA AGTGCTCGTG ACACATAATC ATTCCATCCA ATGATCGCTT TGTGCTT TACCGAGGT TCACGAGCAC TTAGTGAGGC CAAACGAAG ATCCAGGAGT TAAGGTAGGT TAAGGTAGGT TACTAGGGAA AACGAAATGG
	tru9I
	mseI
	bsmAI
	aseI/asnI/vspI
	bsaI
	tsPRI
2201	ACTCTTCCT TTTATCTTAT TAATAAAAAT GTGGTCTCC ACCACTGNCT CCCAAAAAA AAAAAGAAAA AAAAAGAAAA AAAAAGAAAA
	TGAGAAAGGA AAATAGAATA ATTATTTTA CAACCAAGGG TGGTGACNGA GGGTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT

scrFI[M.hpaII-]										
ncII										
mspI										
hpAI										
dsAV	sau96I	rsal								
bssKI	xmaI/pspAI	rsrII/cspI								
	smaI	mroI	nlalIV							
	scrFI[M.hpaII-]	cpoI	kpnI	hpyCH4V						
		hpy188III	csp6I							
aciI	tagI ncII									
fnu4HI/bsoFI	sstI	sall	dsaV	bspMII	banI	sfcI				
haeIII/palI	saci	hincII/hindII	[M.tagI-]	avaiI	[M.hpaII-]					
mciI	eagI/xmaIII/eclXI	aluI	accI	[M.tagI-]	tru9I	mspI	asp718			
eaeI	hgAI/asphI	[M.aluI-]	msel	bspEI	cfr10I	/bsrFI				
cfrI	rmaI	ec1136II	bssKI	aseI/asmI/vspI	acc65I	cac8I				
bsI	maeI	bsp1286	[M.aluI-]	xmnI	tsp509I	bsaWI	pstI			
notI	bfaI	bsiHKAI	bsaJI	tsp509I	bsaWI	ageI	sse6387I			
fnu4HI/bsoFI	bmyI	hpy99I	avai	[M.hpaII-]	hpAI	bspMI	rsal			
aciI	speI	banII	[M.aluI-]	asp700	accIII	hpAI	sbfI			
							sf			
2301	AAAAAAAAA	AAAGGGCGGC	CGCCGACTAG	TGAGCTCGTC	GACCCGGAAA	TTAATTCCGG	ACCGGTACCT	GCAGGGGTAC	CAGCTTTCCC	
	TTTTTTTTT	TTTTTTTTT	TTTCCCCCG	GGGGCTGATC	ACTCGAGCAG	CTGGGCCCTT	AATTAAGGCC	TGGCCATGGGA	CGTCCGCATG	GTCGAAGGG
pleI										
mlyI										
hinfI			aluI							
2401	TATAGTGAGT	CGTATTAGAG	CTTGG							
	ATATCACTCA	GCATAATCTC	GAACC							

> length: 2425

aatII (GACGTC) :	25
acc65I (GGTACC) :	1295 2374
accI (GTTCGAC) :	727 1117 2348
accIII (TCCGGGA) :	2366
aciI (CCGC) :	86 332 355 511 1420 1672 2326 2330
acyI (GRCGYC) :	25
afIIII (ACRYGT) :	37
ageI (ACCGGGT) :	2371
ahaII (GRCGYC) :	25
ahaIII (TTTAAA) :	1914
aluI (AGCT) :	19 48 110 485 569 1006 1680 1781 2016 2343 2392 2419
alw26I (CAGNNNCTG) :	418 523 565
alwI (GGATCNNN) :	270 271 628 785 959 1319 1599 1609 1610 1817 1936
alwNI (CAGNNNCTG) :	418 523 565
apaI (GGGCC) :	533
apoI (RAATTY) :	54 409 841 1249 1381 1879
apyI (CCWGG) :	528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
aseI (ATTAAT) :	1787 2219 2360
asnI (ATTAAT) :	1787 2219 2360
asp700 (GAANNNNTTC) :	375 1159 1379 1469 2358
asp718 (GGTAC) :	1295 2374
aspH1 (GWGCWC) :	484 2152 2342
aspI (GACNNNGTC) :	451
avaII (CYCGRG) :	62 280 995 2353
avaII (GGGCC) :	559 705 909 1140 1985 2143 2369
baII (TGGCCA) :	437
bamHI (GGATCC) :	270 1609
banI (GGYRC) :	640 1295 2374

banII (GRGCGC) :	484	533	809	2342
bbsI (GAAGACNNNNNN) :	130	379	587	
bbvI (GCAGC) :	292	312	315	318
bceAI (ACGGCNNNNNNNNNN) :	502	656		
bfaI (CTAG) :	243	1210	1216	1396
bgII (GCCNNNNGGC) :	535			
bgIII (AGATCT) :	822			
bmyI (GDGCHC) :	159	484	533	809
bpmI (CTGGAG) :	96	258	325	814
bpuAI (GAAGACNNNNNN) :	130	379	587	
bsaAI (YACGTR) :	42			
bsaHI (GRGCGC) :	25			
bsaI (GGTCTCANNNNN) :	1034	2234		
bsaJII (CCNNGG) :	139	359	503	528
bsaWI (WCCGGW) :	1226	2127	2366	2371
bseRI (GAGGAGNNNNNNNN) :	342	749	1270	
bsqI (GTGCAG) :	415	670	1994	
bsh1236I (CGCG) :	38	331	1329	
bsiEI (CGRYCG) :	755	2327		
bsiHKAI (GWGCWC) :	484	2152	2342	
bsiWI (CGTAGC) :	40			
bsII (CCNNNNNNNGG) :	135	184	274	275
bsmAI (GTCTC) :	1034	2235		
bsmAI (GTCTC) :	1034	2235		
bsmFI (GGGACNNNNNNNNNNNN) :	143	202	297	1141
bsoFI (GCNGC) :	85	292	312	315
bsp120I (GGGCC) :	2017	2024	2326	2329
bsp1286 (GDGCHC) :	533			
bspCNI (CTCAGNNNNNNNN) :	159	484	533	809
	563	1050		

bspEI (TCCGGA) : 2366
bspHI (TCATGA) : 1074
bspMI (ACCTGC) : 2377
bspMI (TCCGGA) : 2366
bsrFI (RCCGGY) : 2371
bsrI (ACTGGN) : 384 618 1542
bssKI (CCNGG) : 139 360 528 609 684 813 882 995 996 1038 1113 1137 1144 1239 1342
bssSI (CTCGTG) : 1363 1602 1638 2061 2353 2354
2155
bst4CI (ACNGT) : 643 1354 1573
bstAPI (GCANNNNNTGC) : 641
bstDSI (CCRYGG) : 503 1516
bstF5I (GGATG) : 405 606 857 1068 1203 1605 1844 1857 2175
bstNI (CCWGG) : 528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
bstUI (CGCG) : 38 331 1329
bstXI (CCANNNNNNTGG) : 260 1478
bstYI (RGATCY) : 270 822 1609
btgI (CCRYGG) : 503 1516
btri (CACGTC) : 667
btsI (GCAGTGNN) : 1992
cac8I (GCNNGC) : 31 35 303 675 868 975 2020 2381
cfoI (GCGC) : 330 364 525 800 1328
cfr10I (RCCGGY) : 2371
cfrI (YGGCCR) : 437 500 611 657 1365 2327
cpoI (CGGWCCG) : 2368
csp6I (GTAC) : 41 387 1296 1897 2375 2387
cspI (CGGWCCG) : 2368
ddeI (CTNAG) : 563 1050 1265 1767
dpnI (GATC) : 271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
2183

dpnII (GATC) :	271	628	786	823	960	1090	1320	1566	1599	1610	1644	1812	1817	1937		
	2183															
draI (TTTAAA) :	1914															
draIII (ACNNNGTG) :	532	558	768	1984	2142											
dsal (CCRTGG) :	642															
dsaV (CCNGG) :	503	1516														
eaeI (YGGCCR) :	139	360	528	609	684	813	882	995	996	1038	1113	1137	1144	1239	1342	
eaGI (CGGCCG) :	1363	1602	1638	2061	2353	2354										
earI (CTCTTCNNNN) :	437	500	611	657	1365	2327										
ecI136II (GAGCTC) :	2327															
ecI1XI (CGGCCCG) :	15	487	862	1100	1177											
eco57I (CTGAAAG) :	484	2342														
ecoN1 (CCTNNDNNAGG) :	250	424	474	489	804											
ecoO109I (RGGNCCY) :	396															
ecoRI (GAATTG) :	532	558	768	1984	2142											
ecoriI (CCWGG) :	528	609	813	882	1038	1113	1137	1144	1342	1363	1638	2061				
ecoRV (GATATC) :	1929															
fnu4HI (GCNGC) :	85	292	312	315	318	321	332	508	519	522	567	570	672	1235	1552	1756
	2017	2024	2326	2329												
fnuDII (CGCG) :	38	331	1329													
fokI (GGATG) :	405	606	857	1068	1203	1605	1844	1857	2175							
gsuI (CTGGAG) :	96	258	325	814	883	1290										
haeII (RGCGCY) :	363	524	799													
haeIII (GGCC) :	438	501	534	543	612	658	769	1366	1776	2328						
hgAI (GACGC) :	295	420														
hgIAI (GWGCWC) :	484	2152	2342													
hhAI (GCGC) :	330	364	525	800	1328											
hinPI (GCGC) :	330	364	525	800	1328											

hinclI (GTYRAC) :	2348
hindII (GTYRAC) :	2348
hinflI (GANTC) :	25
hinlII (GRCGTC) :	204 451 585 914 1120 1148 1275 1500 1829 2070 2407
hpalII (CCGG) :	139 361 684 996 1227 1239 1602 2128 2354 2367 2372
hphI (GGTGA) :	3 181 346 1023 1434 1832
hpy188I (TCNGA) :	51 79 252 476 491 582 806 946 1568 1809 1814
hpy188II (TCNNGA) :	97 281 402 443 1051 1074 1209 1289 1446 1873 1933 2156 2366
hpy9I (CGWCG) :	27 2347
hpyCH4III (ACNGT) :	643 1354 1573
hpyCH4IV (ACGT) :	26 43 149 668
hpyCH4V (TGCA) :	34 416 521 671 1030 1283 1524 1995 2023 2051 2104 2380
kpnI (GGTACC) :	1295 2374
ksp632I (CTCTTCNNNN) :	15 487 862 1100 1177
maeI (CTAG) :	243 1210 1216 1396 1504 1805 1849 1889 2140 2337
maeII (ACGT) :	26 43 149 668
maeIII (GTNAC) :	4 180 1435 2158
mboI (GATC) :	271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
mboII (GAAGA) :	2183
mcrI (CGRYCG) :	15 131 380 488 588 825 862 917 1101 1177 1219 1450
mfeI (CAATTG) :	755 2327
mluI (ACGCGT) :	1622
mlyI (GAGTCNNNN) :	37
mnlI (CCTC) :	204 451 585 1120 1500 2407
mroI (TCCGGA) :	65 77 126 185 209 227 246 344 350 396 469 545 562 598 724 749 853
mscI (TGGCCA) :	865 886 1021 1168 1180 1270 1287 1293 1324 1402 1738 1835 2005 2146
mseI (TTAA) :	2366
mslI (CAYNNNNRTG) :	437
	175 1788 1915 1981 2220 2361
	400 1405 1407

mspAII (CMGCKG) :	568	1672												
mspI (CCGG) :	139	361	684	996	1227	1239	1602	2128	2354	2367	2372			
munI (CAATTG) :	1622													
mvaI (CCWGG) :	528	609	813	882	1038	1113	1137	1144	1342	1363	1638	2061		
mvnI (CGGG) :	38	331	1329											
mwoI (GCNNNNNNNGC) :	303	312	315	321	357	502	535	641	650	793	802	1555	1665	
nciI (CCSGG) :	139	360	684	995	996	1239	1602	2353	2354					
ndeII (GATC) :	271	628	786	823	960	1090	1320	1566	1599	1610	1644	1812	1817	1937
	2183													
nlaIII (CATG) :	32	199	336	555	1014	1075	1315	1407	1497					
nlaIV (GGNNCC) :	270	532	533	558	640	705	991	1034	1140	1295	1609	1741	1985	2374
notI (GGGGCCGC) :	2326													
nspBII (CMGCKG) :	568	1672												
nspHII (RCATGY) :	31	335												
nspI (RCATGY) :	31	335												
paeR7I (CTCGAG) :	62													
palI (GGCC) :	438	501	534	543	612	658	769	1366	1776	2328				
pflFI (GACNNNGTC) :	451													
pleI (GAGTCNNN) :	204	451	585	1120	1500	2407								
ppuMI (RGGMCCY) :	558	1984	2142											
pshAI (GACNNNGTC) :	553													
pspAI (CCCGGG) :	995	2353												
pspGI (CCWGG) :	528	609	813	882	1038	1113	1137	1144	1342	1363	1638	2061		
pspOMI (GGGCC) :	533													
pstI (CTGCAG) :	520	2379												
pvuII (CAGCTG) :	568													
rcaI (TCATGA) :	1074													
rmaI (CTAG) :	243	1210	1216	1396	1504	1805	1849	1889	2140	2337				
rsalI (GTAC) :	41	387	1296	1897	2375	2387								
rsrII (CGGMCCG) :	2368													

sacI (GAGCTC) :	484	2342
salI (GTCGAC) :	2348	
sapI (GCTCTTCNNNN) :	15	486
sau3AI (GATC) :	1099	
sau96I (GGNCC) :	271	628
sbfI (CCTGAGG) :	786	823
scrFI (CCNGG) :	960	1090
sfaNI (GCATC) :	1566	1599
sfcI (CTRYAG) :	1599	1610
sfiI (GGCNNNNNGGCC) :	1644	1812
smaI (CCCGGG) :	1717	1937
smlI (CTYRAG) :	2183	
snaBI (TACGTA) :	533	534
speI (ACTAGT) :	559	705
sphI (GCATGC) :	769	909
spI (CGTAGC) :	1140	1776
sse8387I (CCTGCCAGG) :	1985	2143
ssP1 (AATATT) :	2354	2369
sstI (GAGCTC) :	2378	2397
taiI (ACGT) :	1067	1067
taqI (TCGA) :	10	520
tfI (GAWTC) :	2379	2400
thaI (CGCG) :	1363	1602
tliI (CTCGAG) :	1374	1638
tru9I (TTAA) :	2006	2061
tseI (GCWGC) :	2354	2354
tsp45I (GTSAC) :	2354	2354
tsp509I (AATT) :	2354	2354

tsPRI (NNCAAGTGNNN) :		1574	1821	1992	2243
tth111I (GACNNNNGTC) :	451				
vspI (ATTAAT) :		1787	2219	2360	
xbaI (TCTAGA) :		1209			
xhoI (CTTCGAG) :			62		
xholI (RGATCY) :				270	822
xmaI (CCCGGG) :					1609
xmaIII (CGGCCG) :					995
xmnI (GAANNNNTTC) :					2353
					2327
					375
					1159
					1379
					1469
					2358

not found:

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.